EPCAM and Pleural effusion: constructed recombinant oncolytic adenovirus-encoded EpCAM-targeted BiTEs (EnAd-SA-EpCAMBiTE and EnAd-CMV-EpCAMBiTE) and validated their antitumor efficacies in patients with pleural effusions and ascites (45).